Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator

  • Andreas Krause
  • Patrick Brossard
  • Daniele D’Ambrosio
  • Jasper Dingemanse
Original Paper


Ponesimod (ACT-128800), a reversible, orally active, selective S1P1 receptor modulator, prevents the egress of lymphocytes from the lymph node into the systemic circulation. It is currently in clinical development for the treatment of relapsing multiple sclerosis. Modulation of circulating lymphocytes serves as biomarker of efficacy and safety, such that the quantitative characterization of the pharmacokinetic/pharmacodynamic (PK/PD) relationship guides the clinical development of the compound. The availability of a variety of doses, dosing regimens, and treatment durations permitted estimation of the pharmacokinetics characterized by an absorption lag time followed by a sequential zero/first-order absorption and two compartments with first-order elimination. The PD are modeled as an indirect-effect model with rates of appearance and disappearance of lymphocytes in blood with a circadian rhythm and a drug effect on the rate of appearance. The model suggests a circadian variation of 9 % and a maximum inhibition of 86 % of total lymphocyte count with high doses at steady state. It was instrumental for the selection of doses for subsequent studies that confirmed the effect plateau in total lymphocyte count at approximately 0.5 × 109 counts/L.


Population pharmacokinetics/pharmacodynamics S1P1 receptor modulator Total lymphocyte count Indirect-effect model Circadian variation 


  1. 1.
    Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, Kohl C, Steiner B, Clozel M (2011) The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 337(2):547–556. doi: 10.1124/jpet.110.176487 PubMedCrossRefGoogle Scholar
  2. 2.
    Brossard P, D’Ambrosio D, Cavallaro M, Dingemanse J (2010) Differential effects of ACT-128800, a selective S1P1 receptor agonist, on blood-circulating human T-lymphocyte subpopulations. Poster presented at the 111th Am Soc Clin Pharmacol Ther (ASCPT) meeting, Atlanta, GA, 17–20 March, 2010 Poster PIII-82. Clin Pharmacol Ther 87(S1):S56Google Scholar
  3. 3.
    Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972):355–360. doi: 10.1038/nature02284 PubMedCrossRefGoogle Scholar
  4. 4.
    Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309(5741):1735–1739. doi: 10.1126/science.1113640 PubMedCrossRefGoogle Scholar
  5. 5.
    Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J (2013) Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P receptor modulator, in the first-in-human study. Br J Clin Pharmacol 76(6):888–896. doi: 10.1111/bcp.12129 PubMedCrossRefGoogle Scholar
  6. 6.
    Brossard P, Scherz M, Halabi A, Maatouk H, Krause A, Dingemanse J (2014) Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol 54(2):179–188. doi: 10.1002/jcph.244 CrossRefGoogle Scholar
  7. 7.
    Reyes M, Brossard P, Chassard D, Hoch M, Dingemanse J (2014) Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive. Eur J Clin Pharmacol 70(3):287–293. doi: 10.1007/s00228-013-1625-2 PubMedCrossRefGoogle Scholar
  8. 8.
    Brossard P, D’Ambrosio D, Murat I, Dingemanse J (2012) Effects of three different up-titration regimens of ponesimod, a selective S1P1 receptor agonist, on heart rate. Poster presented at the 113th Am Soc Clin Pharmacol Ther (ASCPT) Meeting, National Harbor, MD, 14–17 March, 2012 Poster PII-109. Clin Pharmacol Ther 91(S1):S92–S93Google Scholar
  9. 9.
    Vaclavkova A, Brossard P, Cavallaro M, D’Ambrosio D, Nacarino Martinez A, Morganti A, Pirron U, Schmidt A-G, Zhang-Fu W (2011) AC-058A200: Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to subjects with moderate to severe chronic plaque psoriasis. Pubmed.
  10. 10.
    Holford NH Absorption models using NM-TRAN.
  11. 11.
    Holford NH, Ambros RJ, Stoeckel K (1992) Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm 20(5):421–442PubMedCrossRefGoogle Scholar
  12. 12.
    Braude S, Beck A (2013) Complete blood counts with differential: more accurate reference ranges based on circadian leukocyte trafficking. J Clin Pathol 66(11):909–910. doi: 10.1136/jclinpath-2013-201776 PubMedCrossRefGoogle Scholar
  13. 13.
    Kirsch S, Thijssen S, Alarcon Salvador S, Heine GH, van Bentum K, Fliser D, Sester M, Sester U (2012) T-cell numbers and antigen-specific T-cell function follow different circadian rhythms. J Clin Immunol 32(6):1381–1389. doi: 10.1007/s10875-012-9730-z PubMedCrossRefGoogle Scholar
  14. 14.
    Fisher LE, Ludwig EA, Jusko WJ (1992) Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J Pharmacokinet Biopharm 20(4):319–331PubMedCrossRefGoogle Scholar
  15. 15.
    Holford NH (2012) An introduction to visual predictive checks.
  16. 16.
    Karlsson MO (2008) A tutorial on visual predictive checks.
  17. 17.
    SAS Institute Inc. (2006) Base SAS 9.1.3 procedures guide. SAS Institute Inc., CaryGoogle Scholar
  18. 18.
    R Development Core Team (2009) R: a language and environment for statistical computing. R Foundation for Statistical Computing, ViennaGoogle Scholar
  19. 19.
    Beal SL, Sheiner LB (1989–1998) NONMEM users guides. Icon Development Solutions, Ellicott CityGoogle Scholar
  20. 20.
    Free Software Foundation (2009) GNU Fortran.
  21. 21.
    Metrum Institute (2008) NMQual: A software environment for operating NONMEM.
  22. 22.
    Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558–569. doi: 10.1208/s12248-009-9133-0 PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Hoch M, D’Ambrosio D, Wilbraham D, Dingemanse J (2013) Up-titration study with ponesimod, a selective S1P1 receptor modulator, to assess its maximum tolerated dose in healthy subjects. Oral contribution OC015 presented at the 11th Conference of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Geneva, Switzerland, August 28–31, 2013. Clin Ther 35(8S):e6–e7CrossRefGoogle Scholar
  24. 24.
    Francis G, Kappos L, O’Connor P, Collins W, Tang D, Mercier F, Cohen J (2013) Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler 20(4):471–480. doi: 10.1177/1352458513500551 PubMedCrossRefGoogle Scholar
  25. 25.
    Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A (2011) Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 76(8 Suppl 3):S20–S27. doi: 10.1212/WNL.0b013e31820db341 PubMedCrossRefGoogle Scholar
  26. 26.
    Kasper LH, Shoemaker J (2010) Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 74(Suppl 1):S2–S8. doi: 10.1212/WNL.0b013e3181c97c8f PubMedCrossRefGoogle Scholar
  27. 27.
    Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, Pan S, Gray NS, Hinterding K, Cooke NG, Groenewegen A, Vitaliti A, Sing T, Luttringer O, Yang J, Gardin A, Wang N, Crumb WJ Jr, Saltzman M, Rosenberg M, Wallstrom E (2012) The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 167(5):1035–1047. doi: 10.1111/j.1476-5381.2012.02061.x PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L (2008) FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71(16):1261–1267. doi: 10.1212/01.wnl.0000327609.57688.ea PubMedCrossRefGoogle Scholar
  29. 29.
    Henault D, Galleguillos L, Moore C, Johnson T, Bar-Or A, Antel J (2013) Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis. Neurology 81(20):1768–1772. doi: 10.1212/01.wnl.0000435564.92609.2c PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Hoch M, Vaclavkova A, Stoltz R, Brossard P, Dingemanse J (2013) Thorough QT study with ponesimod, a selective S1P1 receptor modulator. Poster PP162 presented at the 11th Conference of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Geneva, Switzerland, August 28–31, 2013. Clin Ther 35(8S):e68–e69CrossRefGoogle Scholar
  31. 31.
    Vaclavkova A, Chimenti S, Arenberger P, Holló P, Sator P-G, Burcklen M, Stefani M, D’Ambrosio D (2014) A multicentre, randomised, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy, safety and tolerability of ponesimod, an oral sphingosine 1-phosphate receptor-1 modulator, in patients with chronic plaque psoriasis. Lancet (to appear)Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Andreas Krause
    • 1
  • Patrick Brossard
    • 1
  • Daniele D’Ambrosio
    • 2
  • Jasper Dingemanse
    • 1
  1. 1.Department of Clinical PharmacologyActelion Pharmaceuticals LtdAllschwilSwitzerland
  2. 2.Department of Clinical Science & EpidemiologyActelion Pharmaceuticals LtdAllschwilSwitzerland

Personalised recommendations